Literature DB >> 27524390

Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England.

H J A Van Ruiten1, C Marini Bettolo2, T Cheetham3, M Eagle2, H Lochmuller2, V Straub2, K Bushby2, M Guglieri4.   

Abstract

INTRODUCTION: Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease in children. Recent years have seen an increase in age of survival into adulthood following the introduction of proactive standards of care. We reviewed mortality in DMD in our population in order to identify potential underlying risk factors for premature death and improve clinical care.
METHOD: A retrospective case note review of all deaths in the DMD population over the last 10 years in North East England. We identified 2 groups of patients: patients who died from underlying cardiac and/or respiratory failure (group 1) and patients who died unexpectedly in the absence of underlying cardio-respiratory failure (group 2).
RESULTS: Detailed information was available on 21 patients. Mean age of death in group 1 (17 patients) was 23.9 (14.4-39.5) years, in group 2 (4 patients) 14 (12.7-14.9) years. Causes of death in group 2 were acute pneumonia, cardiac arrest, acute respiratory distress and multi-organ failure. Across both groups we identified concerns regarding respiratory failure, inadequate nutrition, non-attendance at appointments, suboptimal coordination of care and decreased psychological wellbeing. In group 2, fat embolism, cardiac arrhythmia and adrenal insufficiency were also potential contributing factors.
CONCLUSIONS: The main cause of death in DMD in our population remains cardio-respiratory failure. Four patients (19%) died in their teenage years in the absence of severe cardiorespiratory failure. A more thorough understanding of the impact of DMD and its treatment on all organs systems is required to minimise the risk of an untimely death. Crown
Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Duchenne muscular dystrophy; Mortality; Premature death

Mesh:

Substances:

Year:  2016        PMID: 27524390     DOI: 10.1016/j.ejpn.2016.07.020

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  24 in total

1.  Electrical storm in a patient with Duchenne muscular dystrophy cardiomyopathy triggered by abrupt β-blocker interruption.

Authors:  Nikolaos Fragakis; Melani Sotiriadou; Lydia Krexi; Vassilios Vassilikos
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-06-15       Impact factor: 1.468

Review 2.  Clinical management of Duchenne muscular dystrophy: the state of the art.

Authors:  Sonia Messina; Gian Luca Vita
Journal:  Neurol Sci       Date:  2018-09-14       Impact factor: 3.307

3.  Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.

Authors:  Daniela J Conrado; Jane Larkindale; Alexander Berg; Micki Hill; Jackson Burton; Keith R Abrams; Richard T Abresch; Abby Bronson; Douglass Chapman; Michael Crowther; Tina Duong; Heather Gordish-Dressman; Lutz Harnisch; Erik Henricson; Sarah Kim; Craig M McDonald; Stephan Schmidt; Camille Vong; Xiaoxing Wang; Brenda L Wong; Florence Yong; Klaus Romero
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-24       Impact factor: 2.745

4.  Expiratory dysfunction in young dogs with golden retriever muscular dystrophy.

Authors:  Eleanor C Hawkins; Amanda K Bettis; Joe N Kornegay
Journal:  Neuromuscul Disord       Date:  2020-09-20       Impact factor: 4.296

5.  Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; Paulina Langa; Sonia Brodowska; Katarzyna Kozlowska; Kristina Zalants; Katarzyna Budzynska; Ahlke Heydemann
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 6.692

Review 6.  Cardiovascular Disease in Duchenne Muscular Dystrophy: Overview and Insight Into Novel Therapeutic Targets.

Authors:  Taylor I Schultz; Frank J Raucci; Fadi N Salloum
Journal:  JACC Basic Transl Sci       Date:  2022-03-09

7.  Differentiation of Pediatric-Onset Duchenne and Becker Muscular Dystrophy Subphenotypes Using Data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet).

Authors:  Jennifer G Andrews; Molly M Lamb; Kristin M Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Shree Pandya
Journal:  J Neuromuscul Dis       Date:  2022

8.  Defective Flux of Thrombospondin-4 through the Secretory Pathway Impairs Cardiomyocyte Membrane Stability and Causes Cardiomyopathy.

Authors:  Matthew J Brody; Davy Vanhoutte; Tobias G Schips; Justin G Boyer; Chinmay V Bakshi; Michelle A Sargent; Allen J York; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

9.  Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies.

Authors:  Larry W Markham; Jonathan H Soslow; Aryaz Sheybani; Kim Crum; Frank J Raucci; William B Burnette
Journal:  Pediatr Res       Date:  2021-08-24       Impact factor: 3.756

Review 10.  Dystrophic Cardiomyopathy: Complex Pathobiological Processes to Generate Clinical Phenotype.

Authors:  Takeshi Tsuda; Kristi K Fitzgerald
Journal:  J Cardiovasc Dev Dis       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.